1. Papers Published or In Press


78. Kolosova I, Nethery D, Kern JA. Role of Smad2/3 and P38 MAP kinase in TGF-ß1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. *J Cell Physiol*, 2011; 226:1248-54. PMID 20945383, PMC 3043117, NIHMS 258150


89. Carr, Laurie; Chung, Jonathan; Achcar, Rosane; Lesic, Zoran; Rho, Ji Young; Yagihashi, Kunihiro; Tate, Robert; Swigris, Jeffrey; Kern, Jeffrey. The Clinical Course of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. *Chest* 2015 Feb; 147(2): 415-22. doi: 10.1378/chest.14-0711 PMID 25275948

2. Books and/or Chapters


3. Reviews, Editorials and Other


4. Abstracts:


45. Kernstine, K.H., Trapp, J.J., Kirchner, P.T., Galvin, J.R., Rossi, N.P., and Kern, J.A. Comparison to Positron Emission Tomography (PET) and Computed (CT) to Identify N2 and N3 Disease in Non-Small Cell Lung Cancer (NCSLC) The Society of Thoracic Surgeons, Aug 4, 1997


47. Kernstine, K., Trapp, J., Croft, D., Kirchner, P., Stanford, W., Galvin, J., Mullin, B., Rossi, N., McLaughlin, K., and Kern, J. FDG-Positron Emission tomography (PET), Computed Tomography (CT) and Magnetic Resonance Imaging with Combidex (MRI-C) to Stage the Mediastinum in Non-Small Cell Lung Cancer (NSCLC). Society of Thoracic Surgeons, July 31, 1998 (Accepted abstract)


64. A Dowlati, T Cortas, R Eisenberg, P Fu, J Robke, J Kern. Activation State (Phosphorylated) EGFR and STAT-3 as Prognostic Markers in Resected Non-Small Cell Lung Cancer (NSCLC). AACR National Meeting, April, 2005.


68. Tania Cortas, Amy Kluge, David Nethery, Jeffrey Kern, Afshin Dowlati. Constitutive activation of Src and downstream STAT3 in small cell lung cancer (SCLC) can be targeted and results in growth inhibition. AACR National Meeting, Washington DC, 2006


74. Patrick C. Ma, Shan Jiang, Runlei Du, Sascha Dietrich, Zhe Tang, Jeffrey A. Kern. Modeling Targeted Inhibition of Wild Type and Mutated c-MET Receptor (ASCO National Meeting, 2007)


5. David Nethery, BA, Rangnath Mishra, PhD, Emily Wilkinson, BS, Mohammad Shatat, MD, David Wyler, MD, James Finigan, MD and Jeffrey A. Kern, MD. Bleomycin-induced Injury of Epithelial Cell Monolayers is HER2 and ADAM-17 Dependent. ATS National Meeting, May 2010

6. Rangnath Mishra, PhD, Jihane Faress, MD, David Nethery, BA, Emily Wilkinson, BS, Mohammad Shatat, MD, David Wyler, MD, James Finigan, MD and Jeffrey A. Kern, MD. ADAM17 plays a crucial role in mediating IL-1β-induced inflammatory signaling through HER2 and ERK-1. ATS National Meeting, May 2010

7. Shatat, M, Nethery, D, Mishra, R, Wilkinson, E, Wyler, D, Finigan, J, Kern, JA. IL-1β Mediated HER2 Transactivation Alters Pulmonary Epithelial Barrier. ATS National Meeting, May 2010


Other: Exhibits, Films, Tapes, Special Presentations


32. UHHS System Grand Rounds. ARDS. April, 2002


37. Department of Medicine Grand Rounds, Case Medical School, “Hyperglycemia in the ICU; Finding the Sweet Spot” June, 2005

38. Department of Medicine Grand Rounds, University of Wisconsin, Madison, Wisconsin, “ARDS”. October 10, 2005

39. Division of Pulmonary and Critical Care Grand Rounds, University of California – Los Angeles. “EGFR family in the recovery from lung injury”, December 6, 2005


43. Neurocritical Care 2008, Symposium moderator, Medical Issues in the NSICU, Cleveland, OH September 13, 2008


45. National Jewish Health Grand Rounds. HER2 Signaling in the Pulmonary epithelium: Implications for Wound Repair and Tumorigenesis”, January 14, 2009

46. University of Toledo, Department of Medicine, “ARDS: the Protection Racket”. Grand Rounds, February 19, 2009

47. University of Toledo, Cancer Center Research Seminar “HER2 Signaling in the Pulmonary Epithelium; Implications for tumorigenesis and wound Healing”, February 19, 2009

48. University of Cincinnati, Pulmonary, Critical Care and Sleep Division Grand Rounds, Department of Medicine, “HER2 Signaling in the Pulmonary Epithelium; Implications for Wound Healing”, March 2, 2009

49. National Jewish Health, Department of Medicine Grand Rounds, “Beyond Traditional Therapy: Molecular Medicine for Lung Cancer”. Denver, CO, March 15, 2010


51. Exempla Hospital System, Good Samaritan Hospital, Grand Rounds Department of Medicine, “Pulmonary Nodules: Has CT Really Helped Us?”, July 22, 2010

53. Invited Speaker as a faculty member of the 2011 ATS SOTA Course in Pulmonary Critical Care and Sleep, March 3, “Lung Cancer 2011”, San Diego, California


56. Visiting Professor, Medicine Grand Rounds Speaker Rhode island Hospital, Jan 31, 2012, “The Great Debate: Screening for Lung Cancer”, Providence, Rhode Island

57. Visiting Professor, Pulmonary Research Conference, Brown University, Jan 30, 2012, “HER2 Regulation of Pulmonary epithelial Permeability”. Providence, Rhode Island

58. Invited Speaker as a faculty member of the 2012 ATS SOTA Course in Pulmonary Critical Care and Sleep, March 2, “Lung Cancer in 2012”, Dallas, Texas


60. Keynote Speaker at University of California Sacramento Grand Rounds, October 20, 2012, “The Key to Personalized Oncology: Molecular Pathology”, Fresno, California


63. Symposium Organizer, “Guidelines for Non-Small Cell Lung Cancer Customized Care”, National Jewish Health, October 17, 2013

64. National Jewish Health, Department of Medicine Grand Rounds, “Tools for Personalized and Precise Lung Cancer Care”, Denver, CO, November 4, 2013

65. Lymphangiolyomatosis International Research Conference, “Functional Genomics of Lung Cancer: HER2 to the Kinome”. Chicago, IL, March 29, 2014,


71. Medical Grand Rounds, Gunderson Clinic, October 13, 2016

72. Medical Grand Rounds, University of Texas Medical Branch – Amarillo, 2016